BCL2 and B-cell chronic lymphocytic leukemia: Blombery et al., recently published data in a cohort of 67 patients with relapsed CLL treated with venetoclax [106] implicating the recurrent novel BCL2 mutation, Gly101Val, in treatment refractoriness.